This report will not include the 220 plots where Fluazinam was screened on potential runner-type lines that may show promise for growers in some counties. Important progress have been made in getting a Section 18 for use in North Carolina for next season. Dr. Bailey has been working closely with company representatives and Dr. Phipps in overcoming the hurdles with the EPA to get this product on the market. The following is a summary of the comments that will be made by Andrea Lemay. An appendix of additional Sclerotinia blight data from another study follows.
Sclerotinia blight causes serious yield loss in North Carolina.
A field test was implemented to study genotype resistance, and the effect of the experimental chemicals, fluazinam and actigard on disease incidence. Thirteen genotypes were seeded in two 7.6m row plots, in a RCBD with three repetitions on 19, May 1997. Newly developed lesions were counted weekly in 1997 and every other week in 1998. In 1998, Fluazinam lowered disease on some genotypes. A final disease rating also was made of all Sclerotinia blight symptoms in 1997, where Fluazinam lowered disease incidence on several genotypes.